AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 133 min read$JNJ

Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook

Johnson & Johnson (JNJ) reported Q3 2026 earnings of $2.59 per share, beating estimates, with revenue up 5.9% to $25.4B. The company raised its full-year outlook, forecasting EPS of $11.05-$11.15 and revenue of $101.0B-$101.4B. Growth was driven by Innovative Medicine and MedTech divisions, with US sales outperforming international.

Original reporting
finance.yahoo.com
Published Oct 13, 2026, 12:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$JNJBullishHigh
01

Why it matters

The earnings beat and guidance lift provide fresh material for traders to adjust positions, especially in health‑care focused portfolios.

02

Market read

Primary earnings release for a large‑cap health company; immediate relevance for equity traders and sector funds.

03

What to watch

Potential headwinds from regulatory scrutiny on drug pipeline and upcoming patent expiries could temper long‑term upside.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Johnson & Johnson reported Q3 2026 results, beating EPS estimates and raising full‑year guidance for earnings and revenue.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Q3 2026 earnings beat expectations and full-year guidance raised to $11.05-$11.15 EPS, $101.0-$101.4B revenue.

Expected impact

likely modest upward pressure as investors price in higher earnings outlook

Evidence & confidence

Earnings beat and raised guidance are fresh primary data for a large-cap health company, prompting a small price move and potential re‑rating.

Market effects

Sector

May lift broader healthcare and pharma indices as peers are re‑priced on stronger demand trends.

Regional

U.S. market may see slight gain in health‑care ETFs.

Global

Limited; primarily affects U.S. and global health‑care investors.

Counterpoint

What could challenge this read

Guidance still below consensus revenue midpoint; skeptics may view the raise as modest and price in further upside.

Key entities

  • company
    Johnson & Johnson

    U.S. health‑care conglomerate reporting Q3 earnings.

Read at source← All news

StoryJohnson & Johnson reports Q3 2026 earnings and lifts full‑year sales and EPS guidance

Also covered by

4 outlets

Related articles

OCT 13
$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

247wallst.com7 min
OCT 13
$JNJHighAI 8/10

Tremfya rescues J&J’s immunology sales to fuel strong Q3

Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.

finance.yahoo.com2 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson raises 2026 guidance as quarterly sales climb

Johnson & Johnson (JNJ) raised its 2026 sales and earnings forecasts after Q3 sales grew 6%. Full-year sales midpoint increased to $101.2B, and adjusted EPS midpoint rose by $0.06 to $11.10. Q3 sales reached $25.4B, with adjusted EPS at $2.59. Growth was driven by Innovative Medicine and MedTech divisions, while Stelara sales declined. Shares fell over 5% on the news.

finance.yahoo.com2 min
OCT 13
$JNJHighAI 9/10

J&J Q3 2026 slides: $25.4B revenue, OTTAVA FDA win, margins pressured

Johnson & Johnson (JNJ) reported Q3 2026 revenue of $25.4B, up 5.9%, but shares fell 4.36% due to margin pressure. Adjusted EPS declined 7.5% YoY to $2.59. U.S. sales grew 9.1%, while international sales rose 1.8%. Innovative Medicine saw 7.9% growth, but MedTech lagged with 2.5% growth. The FDA approved the OTTAVA Robotic System, a new surgical robotics category. The company raised its full-year 2026 guidance.

investing.com2 min